Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

A composition, diabetes technology, applied in the field of compositions for controlling blood sugar levels, new therapies or combination therapies, capable of solving problems such as loss of beta cell function, loss of efficacy, harmful side effects, etc.

Inactive Publication Date: 2015-10-14
PHARNEXT
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of these drugs have shown deleterious side effects such as weight gain, peripheral edema or congestive heart failure, and loss of efficacy with long-term use [9]
[0008] Despite the increasing number of treatment options associated with diabetes, none of them reverse all aspects of the disease, including the progressive loss of beta-cell function and control of all complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
  • Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
  • Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Examples

Experimental program
Comparison scheme
Effect test

specific example

[0322] -Acamprosate, about 9mg to 200mg per day orally;

[0323] -Amitriazine, about 0.5mg to 10mg per day orally;

[0324] -Amlexanox, about 0.75mg to 15mg per day orally;

[0325] -Azelastine, about 0.04mg to 0.4mg per day orally;

[0326] -Baclofen, about 0.15mg to 50mg per day orally;

[0327] -Pentovirin, about 0.6mg to 18mg per day orally;

[0328] -Cimetidine, about 4mg to 160mg per day orally;

[0329] -Cinacalcet, about 0.3mg to 36mg per day orally;

[0330] -D-Mannose, 0.01g to 1.6g per day orally;

[0331] -Debrompheniramine, about 0.06mg to 1.2mg per day orally;

[0332] -Ethamine, orally, about 0.6 mg to 600 mg per day;

[0333] -Dihydroxyprophylline, about 9mg to 320mg per day orally;

[0334] -Fenspiril, 1.6 mg to 24 mg orally per day;

[0335] -Fexofenadine, 1.2mg to 18mg per day orally;

[0336] -Idebenone, about 4.5mg to 225mg per day orally;

[0337] -Ifenprodil, about 0.4mg to 6mg per day orally;

[0338] -Levosimendan, about 0.05mg to 4mg per day orally;

[0339] -Metformin, ab...

Embodiment

[0352] Diabetes is a metabolic disease that extremely affects energy homeostasis, and the high plasma levels of glucose observed in patients can have many causes. Type 1 diabetes is characterized by the destruction of the beta cells of the pancreatic islets. Type 2 diabetes is characterized in part by decreased insulin production by pancreatic beta cells, progressive death of beta cells, insulin resistance (ie, lower glucose capture by muscle cells and fat cells), or abnormal liver gluconeogenesis Elevated. Therefore, based on several in vitro and in vivo studies, the efficacy of candidate compounds is determined to address most of the metabolic and physiological damages that characterize this complex pathology. First test the drugs individually and then test their combined effects. A variety of models are given to determine the activity of the drug, which indicates different physiological characteristics that represent abnormal blood glucose levels, such as blood glucose lev...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.

Description

Technical field [0001] The present invention relates to compositions and methods for controlling blood sugar in a mammal in need. In particular, the present invention relates to a new therapy or combination therapy for diabetes and related disorders, the new therapy or combination therapy based on a composition for controlling blood glucose levels. Background technique [0002] Diabetes refers to a group of metabolic diseases in which patients have high blood sugar levels. Since 171 million people in the world, equivalent to 2.8% of the total population in 2000, are diabetic patients, so many patients are affected. Therefore, diabetes is a major public health problem. Currently, diabetes is considered an epidemic: by 2030, the number of patients will almost double. There are two main types of diabetes. The main feature of type 1 diabetes is insulin-dependent patients. Type 1 diabetes is called an autoimmune disease and is sometimes caused by infection. Type I diabetes usually...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61K31/138A61K31/16A61K31/197A61K31/216A61K31/437A61K31/44A61K31/445A61K31/519A61K31/53A61K31/55A61K31/7004A61P5/48A61K31/422
CPCA61K31/122A61K31/137A61K31/138A61K31/16A61K31/197A61K31/216A61K31/4164A61K31/42A61K31/422A61K31/437A61K31/44A61K31/445A61K31/495A61K31/519A61K31/53A61K31/55A61K31/7004A61K31/155A61K31/164A61K31/196A61K31/435A61K31/48A61P43/00A61P5/48A61P5/50A61P3/10A61K2300/00A61K45/06
Inventor 丹尼尔·科恩伊利亚·丘马克威赛尔格·纳比洛克基恩鲁道夫·哈吉
Owner PHARNEXT